AKT1 and hepatocellular carcinoma: Recent results have shown that CD133 may interact with the regulatory subunit of PI3K, stabilizing AKT signalling and conferring CSC‐like properties to hepatocellular carcinoma (Jang et al., 2017a,2017b).